Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Jasper Therapeutics Inc (JSPRW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: JSPRW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 26.17% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.73 | 52 Weeks Range 0.06 - 0.25 | Updated Date 05/31/2025 |
52 Weeks Range 0.06 - 0.25 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.5% | Return on Equity (TTM) -101.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9908441 |
Shares Outstanding - | Shares Floating 9908441 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Jasper Therapeutics Inc
Company Overview
History and Background
Jasper Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of engineered hematopoietic stem cell (HSC) therapies. Founded in 2016, it aims to provide curative potential for patients with life-threatening hematologic diseases through HSC transplants.
Core Business Areas
- Stem Cell Therapy Development: Focuses on developing and commercializing novel therapies based on engineered hematopoietic stem cells (HSCs).
- Hematologic Disease Treatment: Aims to provide curative options for patients with severe hematologic diseases, including inherited anemias and autoimmune disorders.
Leadership and Structure
The company's leadership includes key executives in research, development, and business operations. The organizational structure involves departments dedicated to preclinical research, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Briamimogene lomilogenase tovorafenib: Jasper is developing Briamimogene lomilogenase tovorafenib (formerly JSP457), an anti-c-KIT monoclonal antibody, for stem cell transplant conditioning. This product is in clinical trials to reduce the toxicity associated with traditional conditioning regimens. Competitors in conditioning regimens include companies using chemotherapy and radiation. Market share data is not yet available due to the product being in the clinical stage.
Market Dynamics
Industry Overview
The industry is characterized by significant unmet needs for patients requiring HSC transplants, driving innovation in conditioning regimens and cell engineering.
Positioning
Jasper is positioned as an innovator in the HSC therapy space, with a focus on less toxic conditioning regimens to broaden the applicability of transplants.
Total Addressable Market (TAM)
The TAM for stem cell transplant conditioning is estimated at several billion dollars globally. Jasper is positioned to capture a significant portion of this market with its innovative conditioning regimen.
Upturn SWOT Analysis
Strengths
- Novel conditioning regimen technology
- Potential for reduced toxicity in transplants
- Experienced management team
Weaknesses
- Clinical stage company with no approved products
- Limited financial resources compared to larger companies
- Dependence on clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of indications for its conditioning regimen
- FDA approval and commercialization of product
Threats
- Clinical trial failures
- Competition from established conditioning regimens
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- BMRN
- ABBV
- TAK
Competitive Landscape
Jasper competes with established conditioning regimens and larger pharmaceutical companies, but its novel approach offers potential advantages in safety and efficacy.
Growth Trajectory and Initiatives
Historical Growth: The company's growth is reflected in the advancement of its clinical programs.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of its conditioning regimen.
Recent Initiatives: Recent initiatives include enrollment in ongoing clinical trials and partnerships with research institutions.
Summary
Jasper Therapeutics is a clinical-stage company with potential in HSC transplant conditioning using a novel approach to traditional methods. While no products are currently approved, successful clinical trials could drive significant stock appreciation. Jasper needs to overcome the inherent risks of clinical development, and manage its resources, while navigating through a landscape of larger and established competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-01-10 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://jaspertx.com |
Full time employees 64 | Website https://jaspertx.com | ||
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.